Barriers to Adopting Agile Practices when Developing Medical Device Software

Martin McHugh  
*Technological University Dublin*, martin.mchugh@dit.ie

Fergal McCaffery  
*Dundalk Institute of Technology*, fergal.mccaffery@dkit.ie

Valentine Casey  
*Dundalk Institute of Technology*, val.casey@dkit.ie

Follow this and additional works at: [https://arrow.dit.ie/scschcomcon](https://arrow.dit.ie/scschcomcon)

Part of the [Computer Sciences Commons](https://arrow.dit.ie/scschcomcon)

Recommended Citation
Mc Hugh, M., McCaffery, F., Casey, V.: Barriers to Adopting Agile Practices when Developing Medical Device Software. The 12th International SPICE Conference Process Improvement and Capability dEtermination, 2012, Majorca, Spain
Barriers to Adopting Agile Practices when Developing Medical Device Software

Martin McHugh, Fergal McCaffery, and Valentine Casey
Regulated Software Research Group, Department of Computing and Mathematics, Dundalk Institute of Technology & Lero, Dundalk Co. Louth, Ireland
{martin.mchugh, fergal.mccaffery, val.casey}@dkit.ie

Abstract. Agile methodologies such as XP and Scrum are founded upon the four values and twelve principles of agile software development. A software development project is only considered to be truly agile if these values and principles are followed. However, software developed for use in medical devices must be regulatory compliant and this can make the process of following a single agile methodology such as XP difficult to achieve. This paper outlines how we identified the barriers to agile adoption in the medical device software domain through performing a survey. These barriers include: lack of documentation; maintaining traceability; regulatory compliance; lack of up front planning and the process of managing multiple releases. Based on this research recommendations are also made as to how these barriers can be overcome.

Keywords: Safety Critical, Agile, Plan Driven, XP, Scrum, Barriers, Medical

1 Introduction

Software is playing an increasingly important role in healthcare [1]. As the reliance on this software is increasing, regulatory controls are evolving to ensure the safe and reliable performance of medical devices, to prevent harm to patients, clinicians and third parties.

Software is developed in accordance with a customer’s requirements. Software used as a medical device or as part of a medical device must also be developed in accordance with the regulatory requirements of the region in which the device is being marketed [2]. The generic software development industry has benefited from adopting agile practices [3]. These practices are procedures defined as being highly effective and efficient [4] such as sprint planning, an open office space, daily meetings and product backlogs from Scrum, these have the added benefit of being more cost effective [5]. However, there is a low rate of agile adoption amongst safety critical software developers [6]. The reasons for this are still being investigated. This paper presents research performed to identify the barriers to adopting agile practices when developing medical device software.
As part of this research, a survey was conducted amongst medical device software development organisations in Ireland. This paper also provides recommendations as to how these barriers may be overcome.

The remainder of this paper is structured as follows; in section 2, we present the challenges faced by medical device software developers. In section 3, we outline the survey conducted and present the results. In section 4, we examine each of the barriers identified in section 3 and recommendations are presented as to how these barriers can be overcome. Finally, in section 5, we present our conclusions and outline how this work will contribute to future research.

## 2 Challenges to Developing Medical Device Software

Software developed for use as a medical device or as part of a medical device in Europe must conform to the latest amendment to the Medical Device Directive (MDD) 2007/47/EC [7] and the guidance of the associated MED DEV [8] document. Software developed as a medical device or part of a medical device in the US must conform to the FDA 21 CFR Part 820 [9] Quality System Regulations and conformance is recommended to one or more of the following Food and Drug Administration (FDA) guidance documents:

- General Principles of Software Validation (GPSV) [10];
- Medical Device Data Systems Rule [11];
- Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices [12];
- Draft Guidance for Industry and Food and Drug Administration - Mobile Device Applications [13];
- Guidance for Industry, FDA Reviewers and Compliance on Off-The-Shelf Software use in Medical Devices [14].

Both the US and European regulations dictate what information a medical device software development organisation must produce in order to achieve regulatory conformance. However, these guidelines do not mandate the usage of a specific lifecycle to produce this necessary information. IEC 62304:2006 – Medical Device Software – Software life cycle processes [15] is harmonised with the MDD [16] and is approved for use by the FDA. IEC 62304 also does not mandate the usage of a specific lifecycle.

Research conducted at Cochlear [17], Abbott Diagnostics [18], Medtronic [19] and a Danish Pharmaceutical Company [20] revealed that medical device software developers are actively seeking an alternative to traditional plan driven methodologies. These case studies revealed that following agile practices can resolve problems associated with plan driven software development.
3 Barriers to Agile Adoption

As part of their on-going research the authors performed a survey of Irish medical device software development organisations. Twenty medical device software development organisations were surveyed with multiple responses being received from each organisation. The survey revealed that 100% of the respondents who are currently marketing medical device software are developing it for use in Europe. In addition, 79% of these are also developing medical device software for use in the US.

The survey identified that 50% of the organisations are developing software in accordance with the V-Model. An important finding was that another 25% of the organisations are developing medical device software in accordance with agile practices. The remaining 25% of organizations are developing software in accordance with other development lifecycles such as the Waterfall, and Iterative & Incremental approaches. Participants were asked as part of this survey, to identify the barriers to adopting agile practices when developing medical device software. The following issues were identified by participants as barriers:

- Lack of Documentation;
- Traceability Issues;
- Regulatory Compliance;
- Lack of Up-Front planning;
- Managing Multiple Releases.

4 Overcoming Identified Barriers

Five barriers to agile adoption have been identified through the survey as outlined in section 3. Each of these barriers was examined and recommendations made as to how these barriers may be overcome.

4.1 Lack of Documentation

The Agile Manifesto [21] has four key values. One of these values is “Working Software over Comprehensive Documentation”. This value would appear to be a direct contradiction of the regulatory requirements. The FDA regulations require a medical device software development organisation to fully document requirements prior to development [22]. However, Robert Martin, one of the authors of the Agile Manifesto states [21]:

“ Produce no document unless it’s immediate and significant”.

In terms of achieving regulatory compliance, documentation is significant and as such it would still be produced when following agile practices. Research conducted by Berard [23] examined the misconceptions regarding documentation and agile software development. Agile software developers deliver what is requested by the customer. Simply put if a customer/regulatory body requires documentation from an agile
development team there are no barriers in place to prevent the team from producing this documentation whilst still following agile practices.

4.2 Traceability Issues

In order for medical device software development organisations to achieve regulatory approval they must provide evidence of traceability from the requirements specification to each stage of the development process. The FDA General Principles of Software Validation (GPSV) [10] document mandates that code must be linked to requirements and test cases. Using agile practices, requirements are not fixed before development begins and during development changes to requirements are welcomed. However, once the requirements specifications and changes to the requirements specifications are fully documented, traceability can still be maintained. The FDA General Principles of Software Validation state;

“Most software development models will be iterative. This is likely to result in several versions of both the software requirement specification and the software design specification. All approved versions should be archived and controlled in accordance with established configuration management procedures”.

This statement acts as evidence that regulatory bodies acknowledge that requirements can and do change and this is acceptable as long as configuration management procedures are adhered to. This results in requirements that can be used to perform traceability.

Lee et al, [24], present a tool known as “Echo” which can be used to capture requirements as part of an agile development project. This tool provides a mechanism to maintain traceability between the requirements and each stage of development whilst developing software in accordance with agile practices.

4.3 Regulatory Compliance

Regulatory controls and development standards provide guidance in the development of a safe and reliable medical device. However, the MDD, the FDA and the IEC 62304 standard do not enforce the use of a specific software development lifecycle. IEC 62304 states;

“(The IEC 62304) standard does not require a particular software development life cycle model”

As a caveat to the previous statement, IEC 62304 also states;

“Whichever life cycle is chosen it is necessary to maintain the logical dependencies between process outputs”

The FDA GPSV states;
“(the FDA) does not recommend the use of any specific software life cycle model. Software developers should establish a software life cycle model that is appropriate for their product and organization”

The Association of the Advancement of Medical Instrumentation (AAMI), are currently in the process of mapping the principles of the Agile Manifesto to IEC 62304 [25]. As part of this research by the AAMI, each of the 12 agile principles is mapped to a specific stage of development in accordance with IEC 62304. The upcoming release of this document will provide evidence that agile practices can be followed without jeopardising the process of achieving regulatory approval.

4.4 Lack of Up-Front Planning

Plan driven software development lifecycles such as the V-Model place a large emphasis on up-front planning. This up-front planning can provide stability and a point of reference for a development project [2]. However, up-front planning can be difficult to perform following agile practices as requirements changes are welcomed and expected in an agile project [21]. Whilst this is the case, before a project begins agile practices use techniques such as user stories. These are a form of up-front planning [26] and can provide the necessary stability to allow a project to begin.

4.5 Managing Multiple Releases

Software projects developed in accordance with agile practices are divided into iterations. Agile teams attempt to have a potentially shippable system at the end of each iteration [27]. Due to the safety critical nature of medical device software, regulatory requirements prohibit medical device software developers from releasing unfinished software into a live patient environment without being fully tested [10].

However, whilst agile teams typically develop a shippable system during each iteration, this is not a requirement of agile practices. Agile teams can combine components developed during iterations and perform the necessary testing once a number of iterations have been completed. The process of managing multiple releases can be further improved through using third party software tools which are currently available such as “Subversion” [28].

5 Conclusions and Future Work

Research into the usage of agile practices when developing medical device software is still at an early stage. There have been reported successes of utilising agile practices when developing medical device software however, these successes have been performed in isolation and are yet to be replicated.

As a result of the survey outlined in this paper, a number of barriers to agile adoption in the development of medical device software have been identified. Through examination of the relevant medical device regulatory requirements, international standards and guidance documents it may be concluded that none of the
barriers identified are insurmountable. Each of the barriers were analysed in detail and
information has been provided as to how these barriers can be addressed. The
research outlined in this paper is part of a larger study and these results will be used to
assist with further research into the use of agile practices for medical device software
development.

While this research identified the perceived barriers to adopting agile practices
within medical device companies, further research will identify the critical success
factors to using agile practices when developing medical device software. The
research outlined in this paper will also contribute to the development of a software
development lifecycle for medical device software that will integrate the stability of
following a plan driven software development lifecycle with agile practices.

Acknowledgements

This research is supported by the Science Foundation Ireland (SFI) Stokes
Lectureship Programme, grant number 07/SK/I1299, the SFI Principal Investigator
Programme, grant number 08/IN.1/I2030 (the funding of this project was awarded by
Science Foundation Ireland under a co-funding initiative by the Irish Government and
European Regional Development Fund), and supported in part by Lero - the Irish
Software Engineering Research Centre (http://www.lero.ie) grant 10/CE/I1855.

6 References

1. Abraham, C., E. Nishiharas, and M. Akiyama, Transforming healthcare with
information technology in Japan: A review of policy, people, and progress.
2. Ge, X., R.F. Paige, and J.A. McDermid, An Iterative Approach for Development
Orlando, Florida. p. 35-43.
5. Turk, D. and R. France, Assumptions Underlying Agile Software Development
6. Cawley, O., X. Wang, and I. Richardson, Lean/Agile Software Development
Methodologies in Regulated Environments – State of the Art, in Proceedings of
31-36.
8. European Commission, Medical Devices Guidance Document - Qualification
and Classification of stand alone software MEDDEV 2.1/6. 2012.
9. FDA, Title 21--Food and Drugs Chapter I --Food and Drug Administration
Department of Health and Human Services subchapter h--Medical Devices part
820 Quality System Regulation. 2007, U.S. Department of Health and Human
Services.


25. AAMI, *Guidance on the use of agile practices in the development of medical device software TIR-Master_4-00*. 2011, Association for the Advancement of Medical Instrumentation.